Trial Profile
Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Pharmacodynamics; Pharmacokinetics
- 27 Oct 2023 Planned End Date changed from 19 Oct 2023 to 19 Oct 2024.
- 15 Mar 2023 Planned End Date changed from 19 Oct 2022 to 19 Oct 2023.
- 20 Oct 2021 Planned End Date changed from 31 Dec 2021 to 19 Oct 2022.